- Subscribe to eNews
- Buyer's Guide
- About Us
- Special Sections
Amgen Inc. announced that its CEO Kevin Sharer and executive vice president of research Roger Perlmutter will be retiring.
Sharer will step down as CEO effective May 23, 2012, and remain as chairman of the company''s board of directors until Dec. 31, 2012. Robert Bradway, currently president and chief operating officer, will become CEO on May 23, 2012. Amgen said its board of directors plans to elect Bradway chairman when Sharer retires from that position at the end of 2012. The Board will also elect a lead independent director at that time.
Sharer, 63, joined Amgen in 1992 and served as president until 2000 when he was named chairman and CEO.
Bob Bradway joined Amgen in 2006 as a vice president in operations. He was appointed CFO in 2007, and was named president and chief operating officer in 2010. Prior to joining Amgen, Bradway worked for 19 years with Morgan Stanley. Bradway holds a BA in Biology from Amherst College and an MBA from Harvard University.
Roger Perlmutter, MD, will retire as executive vice president of research and development effective Feb. 12, 2012 and will then work with Amgen as a consultant to aid in the transition until Feb. 2013 Perlmutter joined Amgen in 2000.
Sean Harper, MD, will assume his new role on Feb. 13, 2012, reporting to Bradway. Harper will be responsible for Amgen''s global research and development functions. Harper joined Amgen in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety. His current role is senior vice president, global development and he serves as chief medical officer for Amgen. Prior to joining Amgen, Harper worked for six years at Merck Research Laboratories. He attended medical school at UCSF, was board certified in internal medicine and gastroenterology after training at the Massachusetts General Hospital and was a postdoctoral fellow at the Massachusetts Institute of Technology.